Alkermes names Blair Jackson CEO, effective August 1, as pipeline milestones near

Alkermes plc announced on July 28, 2026 that Blair Jackson will assume the Chief Executive Officer role on August 1, 2026, while Richard Pops continues as Chairman of the Board of Directors.¹ Jackson, currently Chief Operating Officer, said the company's first ADHD data for ALKS 7290 are expected in the coming months, and topline results from the alixorexton phase 2 idiopathic hypersomnia study are expected toward year-end¹.

On the commercial side, LUMRYZ, acquired with Avadel, contributed $96.6 million in quarterly revenues, which included approximately $7 million of inventory benefit due to timing of shipments¹. The company also said it recorded a $26.4 million change in the fair value of contingent consideration tied to a CVR milestone from the Avadel acquisition, which was deemed more likely to be achieved following recently announced positive topline results of the phase 3 LUMRYZ study in idiopathic hypersomnia¹.

For full-year 2026, Alkermes kept its total revenue and product-level sales guidance unchanged from the prior outlook issued May 5, 2026, with total revenues still projected at $1,730 million to $1,840 million¹, but it updated its GAAP net loss and EBITDA expectations to reflect the new contingent consideration charge, moving projected GAAP net loss to a range of ($95) million to ($115) million and EBITDA to $75 million to $95 million¹.

On the balance sheet, the company reported cash, cash equivalents and total investments of $691.6 million at June 30, 2026, compared to $538.2 million at March 31, 2026¹. No specific cash runway statement was included in the release.